$-0.15 EPS Expected for MEI Pharma Inc (MEIP)

August 28, 2017 – By Clifton Ray

 $ 0.15 EPS Expected for MEI Pharma Inc (MEIP)

Analysts expect MEI Pharma Inc (NASDAQ:MEIP) to report $-0.15 EPS on September, 5.They anticipate $0.02 EPS change or 11.76 % from last quarter’s $-0.17 EPS. After having $-0.02 EPS previously, MEI Pharma Inc’s analysts see 650.00 % EPS growth. The stock increased 2.39% or $0.06 on August 25, reaching $2.57. About shares traded. MEI Pharma Inc (NASDAQ:MEIP) has risen 20.90% since August 28, 2016 and is uptrending. It has outperformed by 4.20% the S&P500.

MEI Pharma Inc (NASDAQ:MEIP) Ratings Coverage

Among 2 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. MEI Pharma had 6 analyst reports since September 4, 2015 according to SRatingsIntel. Oppenheimer maintained it with “Buy” rating and $6.5000 target in Monday, June 26 report. Oppenheimer maintained MEI Pharma Inc (NASDAQ:MEIP) on Wednesday, August 2 with “Buy” rating. The stock of MEI Pharma Inc (NASDAQ:MEIP) earned “Buy” rating by Oppenheimer on Wednesday, June 14. Oppenheimer maintained the shares of MEIP in report on Wednesday, May 31 with “Buy” rating. On Friday, September 4 the stock rating was maintained by Wedbush with “Hold”.

MEI Pharma, Inc. is an oncology company. The company has market cap of $94.51 million. The Firm is focused on the clinical development of drugs and therapies for treatment of cancer. It has a 159.73 P/E ratio. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143.

More notable recent MEI Pharma Inc (NASDAQ:MEIP) news were published by: Zacks.com which released: “MEI Pharma (MEIP) Shows Strength: Stock Moves 7.6% Higher May 30, 2017” on May 30, 2017, also 247Wallst.com with their article: “Can MEI Pharma Rise Nearly 300%?” published on May 25, 2017, Prnewswire.com published: “MEI Pharma Reports Third Quarter Fiscal Year 2017 Results” on May 04, 2017. More interesting news about MEI Pharma Inc (NASDAQ:MEIP) were released by: Seekingalpha.com and their article: “MEI Pharma: Double Trouble Or Double Double?” published on July 11, 2017 as well as Prnewswire.com‘s news article titled: “Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation …” with publication date: May 18, 2017.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.